These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32776624)

  • 21. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 22. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 23. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S; Sun W; Li M; Dong L
    Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune status could determine efficacy of COVID-19 therapies.
    Cully M
    Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
    [No Abstract]   [Full Text] [Related]  

  • 26. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
    Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine release syndrome in severe COVID-19.
    Moore JB; June CH
    Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
    Smetana K; Brábek J
    In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
    Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
    Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
    Wang Q; Hu Z
    Int J Infect Dis; 2020 Jul; 96():618-620. PubMed ID: 32470601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
    Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
    Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
    Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
    Mantero V; Rigamonti A; Basilico P; Crespi M; Balgera R; Salmaggi A
    J Neurol; 2020 Dec; 267(12):3465-3466. PubMed ID: 32638109
    [No Abstract]   [Full Text] [Related]  

  • 37. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 38. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19.
    Lin JH; Chen YC; Lu CL; Hsu YN; Wang WJ
    J Formos Med Assoc; 2020 Jun; 119(6):1116-1118. PubMed ID: 32359878
    [No Abstract]   [Full Text] [Related]  

  • 39. [Multidisciplinary management of a typical case of acute kidney failure in the course of COVID-19 infection].
    Caputo C; Ciabattoni M; Garneri D; Repetto M; Santoni O; Tarroni A; Tosetti F; Vigo EC; Mancuso G
    G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.